[go: up one dir, main page]

EE200100046A - Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions - Google Patents

Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
EE200100046A
EE200100046A EEP200100046A EEP200100046A EE200100046A EE 200100046 A EE200100046 A EE 200100046A EE P200100046 A EEP200100046 A EE P200100046A EE P200100046 A EEP200100046 A EE P200100046A EE 200100046 A EE200100046 A EE 200100046A
Authority
EE
Estonia
Prior art keywords
acat
administration
treatment
atherosclerotic lesions
mmp inhibitors
Prior art date
Application number
EEP200100046A
Other languages
Estonian (et)
Inventor
Michael Andrew Bocan Thomas
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200100046A publication Critical patent/EE200100046A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
EEP200100046A 1998-07-21 1999-06-18 Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions EE200100046A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
EE200100046A true EE200100046A (en) 2002-06-17

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100046A EE200100046A (en) 1998-07-21 1999-06-18 Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (en)
JP (1) JP2002521328A (en)
KR (1) KR20010083134A (en)
CN (1) CN1310629A (en)
AP (1) AP2001002035A0 (en)
AU (1) AU4701799A (en)
BG (1) BG105162A (en)
BR (1) BR9912296A (en)
CA (1) CA2335062A1 (en)
CZ (1) CZ2001126A3 (en)
EA (1) EA200100153A1 (en)
EE (1) EE200100046A (en)
HR (1) HRP20010055A2 (en)
HU (1) HUP0102880A3 (en)
ID (1) ID30030A (en)
IL (1) IL140982A0 (en)
IS (1) IS5809A (en)
NO (1) NO20010291L (en)
OA (1) OA11584A (en)
PL (1) PL346011A1 (en)
SK (1) SK502001A3 (en)
TR (1) TR200100205T2 (en)
WO (1) WO2000004892A2 (en)
YU (1) YU3501A (en)
ZA (1) ZA200100294B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203160A3 (en) * 1999-11-05 2006-02-28 Warner Lambert Co Prevention of plaque rupture by acat inhibitors
CO5261615A1 (en) 1999-12-01 2003-03-31 Agouron Pharma COMPOUNDS, COMPOSITIONS AND METHODS TO STIMULATE THE GROWTH AND ELONGATION OF NEURONS
CA2393825A1 (en) * 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
AU8254101A (en) * 2000-09-01 2002-03-22 Sankyo Co Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2003229883B2 (en) * 2002-04-03 2009-06-11 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
US7691843B2 (en) * 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (en) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 Use of group of carbamyl phenylsulfonyl compounds
WO2016113713A1 (en) * 2015-01-15 2016-07-21 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (en) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 The effective extract component of river hazel and its application in prevention and treatment atherosclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
DE69707865T2 (en) * 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains BIPHENYLSULFONAMIDE MATRIX METALLOPROTEINASE INHIBITORS
JP2000517341A (en) * 1996-09-04 2000-12-26 ワーナー―ランバート・コンパニー Matrix metalloproteinase inhibitors and their therapeutic use

Also Published As

Publication number Publication date
SK502001A3 (en) 2002-06-04
WO2000004892A2 (en) 2000-02-03
HRP20010055A2 (en) 2002-04-30
ZA200100294B (en) 2002-01-10
CA2335062A1 (en) 2000-02-03
EA200100153A1 (en) 2001-08-27
NO20010291D0 (en) 2001-01-18
AU4701799A (en) 2000-02-14
IL140982A0 (en) 2002-02-10
PL346011A1 (en) 2002-01-14
AP2001002035A0 (en) 2001-03-31
NO20010291L (en) 2001-01-18
CZ2001126A3 (en) 2002-01-16
EP1098662A2 (en) 2001-05-16
HUP0102880A3 (en) 2002-11-28
BG105162A (en) 2001-12-29
ID30030A (en) 2001-11-01
TR200100205T2 (en) 2001-05-21
WO2000004892A3 (en) 2000-05-18
CN1310629A (en) 2001-08-29
HUP0102880A2 (en) 2002-06-29
BR9912296A (en) 2001-04-17
IS5809A (en) 2001-01-12
KR20010083134A (en) 2001-08-31
JP2002521328A (en) 2002-07-16
YU3501A (en) 2005-06-10
OA11584A (en) 2004-07-20

Similar Documents

Publication Publication Date Title
CY2018023I2 (en) SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENIUM COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS
FI971412L (en) Peptididyl compounds and their therapeutic use as metalloprotease inhibitors
EE200100659A (en) Diaminothiazoles and their use for the inhibition of protein kinases
PT977748E (en) SUBSTITUTED BENZOPIRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION
BR9508886A (en) Compounds and methods for the treatment of cancer
ATE245158T1 (en) BICYCLIC HYDROXAMIC ACID DERIVATIVES
ID27394A (en) PHARMACEUTICAL COMBINATIONS CONTAINING COX-2 INHIBITORS AND INOS INHIBITORS
DE59908110D1 (en) CAS DETECTABLE ENDOSCOPE ADAPTER
ID29591A (en) QUINOLINA AND QUINOXALAL COMPOUNDS
EE200100243A (en) 5HT1 receptor agonists and metoclopramide for the treatment of migraine
PT1077940E (en) 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURIGINAL DERMATOSES
ID29943A (en) COMPOUND DDS AND MEASUREMENT METHODS
PT1206436E (en) RETINOIDS FOR THE TREATMENT OF ENFISEMA
EE200100046A (en) Co-administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
ITTO950529A0 (en) DEVICE AND PROCEDURE FOR THE CREATION OF REDUCED LENGTH ORTHODE CHAINS
IT1302811B1 (en) PROCEDURE AND RELATED APPARATUS FOR DIRECT REDUCTION OF IRON OXIDES
IT1301973B1 (en) HYDRO-FLUOROALKYLVINYLETERS AND PROCEDURE FOR THEIR OBTAINING
PT1079818E (en) COMPOSITION UNDERSTANDING IL-18 AND TOPOTECANE FOR THE TREATMENT AND / OR PREVENTION OF CANCER
IT1296305B1 (en) INHIBITORS OF METALLOPROTEINASE THEIR THERAPEUTIC USE AND PROCEDURE FOR THE PRODUCTION OF THE STARTING COMPOUND IN THEIR
ID28032A (en) TRICICLIC OF PIPERIDIN-Δ3-AS ANTAGONIS-α2
NO20004920D0 (en) Use of protease inhibitors for the treatment of skin damage
ID28797A (en) TIOREDOXINATION AND PROCESSING OF SEEDS
EE200100084A (en) New pharmaceutical uses of NOS inhibitors
EE200300057A (en) Ingredients for the prevention and treatment of cancer
PT1200447E (en) OXAZINOCARBAZOLES FOR THE TREATMENT OF DISEASES OF THE SNC